eXoZymes (NASDAQ:EXOZ – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.27) earnings per share for the quarter, Zacks reports.
eXoZymes Trading Down 7.0%
Shares of NASDAQ EXOZ traded down $1.14 on Friday, reaching $15.26. 2,788 shares of the company traded hands, compared to its average volume of 1,978. The stock has a market capitalization of $127.99 million and a PE ratio of -30.52. eXoZymes has a fifty-two week low of $8.86 and a fifty-two week high of $23.99. The company has a current ratio of 6.19, a quick ratio of 6.19 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average of $13.51 and a 200 day moving average of $12.03.
Analyst Ratings Changes
Separately, Weiss Ratings restated a “sell (d-)” rating on shares of eXoZymes in a report on Thursday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.
About eXoZymes
eXoZymes, Inc is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.
Recommended Stories
- Five stocks we like better than eXoZymes
- Investing in Commodities: What Are They? How to Invest in Them
- 3 Under-the-Radar AI Stocks to Buy on the Dip
- What is the S&P/TSX Index?
- Your Thanksgiving Playbook: 3 Stocks Set to Benefit From Football Fever
- Market Cap Calculator: How to Calculate Market Cap
- MarketBeat Week in Review – 11/10 – 11/14
Receive News & Ratings for eXoZymes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for eXoZymes and related companies with MarketBeat.com's FREE daily email newsletter.
